These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 20219015

  • 1. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling.
    Wei Y, Cui C, Lainscak M, Zhang X, Li J, Huang J, Zhang H, Zheng Z, Hu S.
    J Cell Mol Med; 2011 Apr; 15(4):773-82. PubMed ID: 20219015
    [Abstract] [Full Text] [Related]

  • 2. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy.
    Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG.
    Circulation; 1998 May 05; 97(17):1708-15. PubMed ID: 9591765
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
    Spinale FG.
    Circ Res; 2002 Mar 22; 90(5):520-30. PubMed ID: 11909815
    [Abstract] [Full Text] [Related]

  • 6. MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.
    Li H, Simon H, Bocan TM, Peterson JT.
    Cardiovasc Res; 2000 May 22; 46(2):298-306. PubMed ID: 10773234
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.
    Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE.
    Eur J Heart Fail; 2002 Aug 22; 4(4):439-4. PubMed ID: 12167381
    [Abstract] [Full Text] [Related]

  • 9. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis.
    Fielitz J, Leuschner M, Zurbrügg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V.
    J Mol Med (Berl); 2004 Dec 22; 82(12):809-20. PubMed ID: 15558223
    [Abstract] [Full Text] [Related]

  • 10. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy.
    Sivakumar P, Gupta S, Sarkar S, Sen S.
    Mol Cell Biochem; 2008 Jan 22; 307(1-2):159-67. PubMed ID: 17849172
    [Abstract] [Full Text] [Related]

  • 11. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation.
    Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Dorent R, Perennec J, Crozatier B, Harf A, Lafuma C.
    Eur J Heart Fail; 1999 Dec 22; 1(4):337-52. PubMed ID: 10937947
    [Abstract] [Full Text] [Related]

  • 12. Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy.
    Yokoseki O, Yazaki Y, Suzuki J, Imamura H, Takenaka H, Isobe M.
    Jpn Circ J; 2000 May 22; 64(5):352-7. PubMed ID: 10834450
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure.
    Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ.
    Circulation; 2000 Oct 17; 102(16):1944-9. PubMed ID: 11034943
    [Abstract] [Full Text] [Related]

  • 15. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model.
    Mori S, Gibson G, McTiernan CF.
    J Card Fail; 2006 May 17; 12(4):314-25. PubMed ID: 16679266
    [Abstract] [Full Text] [Related]

  • 16. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
    Spinale FG, Coker ML, Bond BR, Zellner JL.
    Cardiovasc Res; 2000 May 17; 46(2):225-38. PubMed ID: 10773226
    [Abstract] [Full Text] [Related]

  • 17. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles.
    Polyakova V, Loeffler I, Hein S, Miyagawa S, Piotrowska I, Dammer S, Risteli J, Schaper J, Kostin S.
    Int J Cardiol; 2011 Aug 18; 151(1):18-33. PubMed ID: 20546954
    [Abstract] [Full Text] [Related]

  • 18. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
    Yang YJ, Zhang X, Zhu WL, Huang Y.
    Zhonghua Yi Xue Za Zhi; 2006 Jun 27; 86(24):1693-6. PubMed ID: 16854324
    [Abstract] [Full Text] [Related]

  • 19. Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.
    Seeland U, Kouchi I, Zolk O, Itter G, Linz W, Böhm M.
    J Mol Cell Cardiol; 2002 Feb 27; 34(2):151-63. PubMed ID: 11851355
    [Abstract] [Full Text] [Related]

  • 20. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.
    Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, Deswal A, Mann DL, Spinale FG.
    J Card Fail; 2002 Dec 27; 8(6):390-8. PubMed ID: 12528092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.